Viruses are being researched as cutting-edge therapeutic agents in cancer due to their selective oncolytic action against malignancies. Immuno-oncolytic viruses are a potential category of anticancer treatments because they have natural features that allow viruses to efficiently infect, replicate, and destroy cancer cells. Oncolytic viruses may be genetically modified; engineers can use them as a platform to develop additional therapy modalities that overcome the limitations of current treatment approaches. In recent years, researchers have made great strides in the understanding relationship between cancer and the immune system. An increasing corpus of research is functioning on the immunomodulatory functions of oncolytic virus (OVs). Several clinical studies are currently underway to determine the efficacy of these immuno-oncolytic viruses. These studies are exploring the design of these platforms to elicit the desired immune response and to supplement the available immunotherapeutic modalities to render immune-resistant malignancies amenable to treatment. This review will discuss current research and clinical developments on Vaxinia immuno-oncolytic virus.
Keywords: Damage-associated molecular patterns (DAMPS); Dendritic cells (DC’s); Human sodium-iodide symporter gene (hNIS); Immunogenic cell death (ICD); Janus kinase-signal transducer and activator of transcription (JAK-STAT); Oncolytic virus (OVs).
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.